Company intelligence / Profile preview

Rubic One Health

South Africa

Ownership: Private
Development stage: Other

Overview

Rubic One Health, using Dyadic's C1 platform, has initiated a Phase 1 trial of the DYAI-100 COVID-19 booster vaccine. The platform has the potential to deliver cost-effective, scalable vaccine and biologics production for both human and animal health in Africa. Ongoing development is focused on broader infectious and chronic disease indications as funding and partnerships expand[4][5][7].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Recombinant proteinMonoclonal antibodyVaccineTherapeutic protein
Industry: Biotech

Partnerships

Dyadic InternationalUniversity of the Witwatersrand (Wits)Wits Health ConsortiumAfreximaxbank

Beyond the preview

Go deeper on Rubic One Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rubic One Health.

Explore the full profile